2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study

(2023) Teerapat Tutaworn et al.   OSTEOPOROSIS INTERNATIONAL

Romosozumab and antiresorptive treatment: the importance of treatment sequence

(2022) Felicia Cosman et al.   OSTEOPOROSIS INTERNATIONAL

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis

(2022) Yang Sun et al.   Frontiers in Pharmacology

UK clinical guideline for the prevention and treatment of osteoporosis

(2022) Celia L. Gregson et al.   Archives of Osteoporosis

Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses

(2022) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk

(2021) Cy Fixen et al.   Current Osteoporosis Reports

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS— 2020 UPDATE

(2021) Pauline M. Camacho et al.   Endocrine Practice

Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study

(2021) Rikako Hiramatsu et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2‐Year Randomized Study

(2021) Anne Sophie Sølling et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)

(2021) Annika Vestergaard Kvist et al.   Journal of Clinical Medicine

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk ( ARCH) trial

(2021) Jacques P. Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis

(2021) Judith Everts‐Graber et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children

(2020) Rocío Galindo-Zavala et al.   Pediatric Rheumatology

Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis

(2020) Houchen Lyu et al.   ANNALS OF INTERNAL MEDICINE

Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS

(2020) Elena Tsourdi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Osteoporosis in Older Adults

(2020) Catherine Bree Johnston et al.   MEDICAL CLINICS OF NORTH AMERICA

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline

(2019) Richard Eastell et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine and Pediatrics

(2019) Christopher R. Shuhart et al.   JOURNAL OF CLINICAL DENSITOMETRY

Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use

(2019) Houchen Lyu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

(2019) Akimitsu Miyauchi et al.   Archives of Osteoporosis

Bone Mineral Density After Transitioning From Denosumab to Alendronate

(2019) David Kendler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

(2018) Nicola Napoli et al.   CALCIFIED TISSUE INTERNATIONAL

Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study

(2018) M. Amine Amiche et al.   Archives of Osteoporosis

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project

(2017) M. Katsoulis et al.   JOURNAL OF INTERNAL MEDICINE

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

(2017) Lenore Buckley et al.   Arthritis & Rheumatology

Epidemiology of Vertebral Fractures

(2016) John T. Schousboe   JOURNAL OF CLINICAL DENSITOMETRY

Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report

(2016) Olivier Lamy et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Postmenopausal Osteoporosis

(2016) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide

(2016) Kenneth G. Saag et al.   Arthritis & Rheumatology

Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders

(2015) Claire MA LeBlanc et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

(2015) Benjamin Z Leder et al.   LANCET

Monitoring of Patients on Long-Term Glucocorticoid Therapy

(2015) Laurence Fardet et al.   MEDICINE

Fracture mortality: associations with epidemiology and osteoporosis treatment

(2014) Sebastian E. Sattui et al.   Nature Reviews Endocrinology

A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children

(2014) Karen E. Hansen et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches

(2014) Felicia Cosman   Current Osteoporosis Reports

GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength

(2013) Jeffrey C. Andrews et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene

(2012) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture

(2011) Edward S. Leib et al.   JOURNAL OF CLINICAL DENSITOMETRY

Guidance for the adjustment of FRAX according to the dose of glucocorticoids

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: A national observational study

(2011) Celia Rodd et al.   ARTHRITIS CARE & RESEARCH

AGREE II: advancing guideline development, reporting and evaluation in health care

(2010) M. C. Brouwers et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

(2010) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know

(2010) A. Catharine Ross et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders

(2010) A. M. Huber et al.   ARTHRITIS CARE & RESEARCH

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

(2010) Jennifer M. Grossman et al.   ARTHRITIS CARE & RESEARCH

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial

(2009) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

(2009) David M Reid et al.   LANCET

A personal perspective on fracture risk assessment tools

(2008) Bruce Ettinger   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: A meta-analysis

(2008) Jurga Adomaityte et al.   THROMBOSIS AND HAEMOSTASIS

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal

Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis

(2007) Steven Boonen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM